Southwest Florida Research (SWFR) is a research center of excellence for the administration of Phase II-IV clinical trials in pharmaceutical and medical devices. We also operate as a healthcare business incubator and market research firm dedicated to researching and sponsoring innovation in healthcare delivery.
Our site research organization is committed to exceeding the needs and expectations of our clients by providing innovative, professional and superior quality service with integrity and reliability.
What We Do
Founded in 2010, Southwest Florida Research (SWFR) grew out of the clinical research division of the Southwest Institute for Cardiovascular Fitness and Treatment (SWICFT). The company is designed as a clinical research collaborative dedicated to partnering pharmaceutical companies with area physicians to find new cures to help patients better manage their healthcare. We share in the commitment and dedication to providing cutting edge therapy that can assist in managing patients’ chronic medical conditions today and for a lifetime.
In the clinical trials area, SWFR offers investigational therapies for indications such as Congestive Heart Failure, Diabetes, and much more. We offer new and existing therapies that manage conditions where other medical therapies may have failed. Each and every patient at SWFR receives the highest quality medical care. We notify the patient’s primary care physician of enrollment and ongoing status and provide a full report at the conclusion of each study.
We are proud to have a number of sub-specialists, internists and others available to work with us on clinical trials in many other clinical areas including cardiology, gastroenterology, neurology, internal medicine, and many others.
- Advance Science and ensure the protection and safety of all patients who choose to participate in our clinical trials.
- Ensure compliance with government regulations.
- Recognize the value of our client, subject, and employee partnerships.
- Exceed customer expectations through a combination of dedication, hard work and perseverance without compromise.
- Champion solutions through innovative thinking.
Phase 4 Registry, Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalaemia or at High Risk of HyperKalaemia
A randomized, double-blind, placebo-controlled study to assess the effects of Bempedoic Acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant
(Esperion Therapeutics, Inc).
ACTIVE-CLOSED TO ENROLLMENT
Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%)
Phase 3, randomized double-blind, placebo-controlled, multicentre trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease.
ACTIVE-CLOSED TO ENROLLMENT
Women's Ischemia Trial to Reduce Events in Non-Obstructive Coronary Artery Disease.
(University of Florida/OneFlorida Consortium)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Assess the Effectiveness of CRD-740 in Patients with Chronic Heart Failure
OPEN TO ENROLLMENT
A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, 2-arm Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
ENROLLMENT STARTING IN FALL
A Phase 3, multicenter, randomized, parallel group, double-blind, placebo-controlled, event-driven study assessing clinical effects of cholesterol ester transfer protein (CETP) inhibition with Evacetrapbid in patients at a high risk for vascular outcomes.
A therapeutic-Equivalence Study comparing the efficacy and safety of intravenous Epoetin Hospira and Eposetin Alfa (Amgen) in patients with Chronic Renal Failure requiring hemodialysis and receiving Epoetin maintenance treatment.
A Cardiovascular Outcomes Study to Evaluate the Potential of Aleglitazar to reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome Event and Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long Term Treatment with BLEVIQ (lorcaserin HCL) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes mellitus on Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy
(Esperion Therapeutics, Inc.)
A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome
(National Heart Lung and Blood Institute)
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
Dapagliflozin Effect of Cardiovascular Events. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Dapagliflozin 10 mg once daily on the incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in patients with Type 2 Diabetes.
ENGAGE AF (TIMI-49)
A Study for the Evaluation of Efficacy and Safety of DU-176b Vs. Warfarin (Coumadin) in Subjects with Atrial Fibrillation
Retrospective Evaluation of the Gore Viabahn Endoprosthesis for a Popliteal Artery Aneurysm Indication. This is a multicenter, non-randomized, single arm, retrospective study of Gore Viabahn Endoprosthesis for the treatment of a Popliteal Artery Aneurysm (PAA).
Getting to an improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States (Amgen)
Multicentre cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease.
A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction.
A Trial to Assess the Prevention of Thrombotic Events with Ticagrelor compared to a Placebo on Patients on ASA (Aspirin) Therapy and a Recent History of Myocardial Infarction
A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease
Randomized Evaluation of dabigatran etexilate Compared to warfarIn In pulmonary vein ablation: assessment of an uninteRrupted periproCedUralantIcoagulation sTrategy
Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy
SAVOR (TIMI 53)
A Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes
A randomized parallel-group, placebo-controlled, double-blind, multicenter dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the oral sGC stimulator BAY 1021189 over 12 weeks in patients with worsening heart failure and preserved ejection fraction (HFpEF) - SOluble Guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF/ REDUCED EF
SPIRE 1 AND 2
Studies of PCSK9 Inhibition and the Reduction of vascular Events. A Phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of Bococizumab (PF-04950615) in reducing the occurrence of major cardiovascular events in high risk subjects.
A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activities of daily living in patients with heart failure and preserved ejection fraction
Phase 2 Randomized, placebo controlled, double-blind, parallel group, dose-finding study to evaluate the efficacy and safety of BAY 2433334 in participants following an acute myocardial infarction.
ACTIVE-CLOSED TO ENROLLMENT